Point-of-care biomarker assay for rapid multiplexed detection of CRP and IP-10

SLAS Technol. 2023 Dec;28(6):442-448. doi: 10.1016/j.slast.2023.10.002. Epub 2023 Oct 14.


Rapid and accurate measurements of immune protein markers are essential for diagnosis and treatment in all clinical settings. The recent pandemic has revealed a stark need for developing new tools and assays that could be rapidly used in diverse settings and provide useful information to clinicians. Here, we describe the development and test application of a novel one-step CRP/IP-10 duplex assay for the LightDeck platform capable of delivering reproducible and accurate measurements in under eight minutes. We used the optimized assay to measure CRP and IP-10 levels in human blood and serum samples from healthy, SARS-CoV-2 (COVID-19) positive, and influenza-like illness (ILI) presenting patients. Our results agreed with previously published analyte levels and enabled us to make statistically significant comparisons relevant to multiple clinical parameters. Our duplex assay is a simple and powerful tool for aiding prognostic decision-making in diverse settings.

Keywords: COVID-19; CRP; CXCL10; IP-10; LightDeck.

MeSH terms

  • Biomarkers
  • C-Reactive Protein / chemistry
  • COVID-19* / diagnosis
  • Chemokine CXCL10 / blood
  • Chemokine CXCL10 / chemistry
  • Humans
  • Point-of-Care Systems*
  • SARS-CoV-2


  • Biomarkers
  • Chemokine CXCL10
  • C-Reactive Protein